Deciphera Pharmaceuticals (DCPH) Initiates Pivotal Phase 3 Clinical Study of Ripretinib in Second-line Patients with Gastrointestinal Stromal Tumors
Tweet Send to a Friend
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
